Buprenorphine treatment in an urban community health center: Wat to expect

Family Medicine

Volumn 40, Issue 7, 2008, Pages 500-506

  Cunningham, Chinazo ^a   Giovanniello, Angela ^a   Sacajiu, Galit ^a   Whitley, Susan ^a   Mund, Pamela ^a   Beil, Robert ^a   Sohler, Nancy ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b CITY UNIVERSITY OF NEW YORK MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ANALGESIC AGENT; BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; METHADONE; OPIATE;

ADULT; AFRICAN AMERICAN; ARTICLE; CLINICAL ARTICLE; COMMUNITY CARE; DRUG DOSE INCREASE; EMPLOYMENT STATUS; FEMALE; HEALTH CENTER; HEALTH PROGRAM; HISPANIC; HUMAN; MALE; MEDICAL RECORD REVIEW; OPIATE ADDICTION; RETROSPECTIVE STUDY; TREATMENT OUTCOME; URBAN POPULATION; URINALYSIS;

BUPRENORPHINE; COMMUNITY HEALTH SERVICES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NALOXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; RETROSPECTIVE STUDIES; SUBSTANCE-RELATED DISORDERS; URBAN HEALTH SERVICES;

EID: 48249141077     PISSN: 07423225     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Crane E. Narcotic analgesics. The Drug Abuse Warning Network (DAWN) Report, 2003. http://oas.samhsa.gov/2k3/pain/DAWNpain. pdf. Accessed November 18, 2007.
2. Office of National Drug Control Policy (ONDCP). Drug Policy Information Clearinghouse. Heroin fact sheet, 2003. www.streetdrugs.org/pdf/Heroin2.pdf. Accessed November 18, 2007.
3. Substance Abuse and Mental Health Services Administration. Office of Applied Studies. Emergency department trends from the Drug Abuse Warning Network, final estimates 1995-2002. Rockville, Md: DAWN Series: D-24, DHHS publication no. (SMA) 03-3780, 2003. http://dawninfo.samhsa.gov/old_dawn/ pubs_94_02/edpubs/2002final/files/EDTrendFinal02AllText.pdf. Accessed November 18, 2007.
4. Kakko J, Svanborg KD, Kreek MJ, Heilig M. One-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet 2003;361(9358):662-8.
5. Effective medical treatment of opiate addiction. National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction. JAMA 1998;280(22):1936-43.
6. Ball JC, Ross A. The effectiveness of methadone maintenance treatment: patients, programs, services, and outcome. New York: Springer-Verlag, 1991.
7. Fiellin DA, O'Connor PG. Clinical practice. Office-based treatment of opioid-dependent patients. N Engl J Med 2002;347(11):817-23.
8. Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med 2003;349(10):949-58.
9. Sees KL, Delucchi KL, Masson C, et al. Methadone maintenance versus 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial. JAMA 2000; 283(10):1303-10.
10. Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med 2000; 343(18):1290-7.
11. O'Connor PG, Fiellin DA. Pharmacologic treatment of heroin-dependent patients. Ann Intern Med 2000;133(1):40-54.
12. Executive Office of the President, Office of National Drug Control Policy. Consultation document on opioid agonist treatment, 2003. www.whitehousedrugpolicy.gov/science%5Ftech/methadone/metha3.html. Accessed November 18, 2007.
13. Kissin W, McLeod C, Sonnefeld J, Stanton A. Experiences of a national sample of qualified addiction specialists who have and have not prescribed buprenorphine for opioid dependence. J Addict Dis 2006; 25(4):91-103.
14. Cunningham CO, Kunins HV, Roose RJ, Elam RT, Sohler NL. Barriers to obtaining waivers to prescribe buprenorphine for opioid addiction treatment among HIV physicians. J Gen Intern Med 2007; 22(9):1325-9.
15. Karpati A, Kerker B, Mostashari F, et al. Health disparities in New York City. New York: New York City Department of Health and Mental Hygiene, 2004. www.nyc.gov/html/doh/downloads/pdf/epi/disparities-2004.pdf. Accessed November 18, 2007.
16. Olson EC, Van Wye G, Kerker B, Thorpe L, Frieden TR. Take care Highbridge and Morrisania. NYC community health profiles, second edition. www.nyc.gov/html/doh/downloads/pdf/data/2006chp-106.pdf. Accessed February 3, 2007.
17. Diagnostic and statistical manual of mental disorders, fourth edition. Washington, DC: American Psychiatric Association, 1994.
18. Center for Substance Abuse Treatment. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS publication no. (SMA) 04-3939. Rockville, Md: Substance Abuse and Mental Health Services Administration, 2004.http:// buprenorphine.samhsa.gov/Bup%20Guidelines. pdf. Accessed February 5, 2007.
19. Wesson DR, Ling W. The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs 2003;35(2):253-9.
20. Stein MD, Cioe P, Friedmann PD. Buprenorphine retention in primary care. J Gen Intern Med 2005;20(11):1038-41.
21. Alford DP, LaBelle CT, Richardson JM, et al. Treating homeless opioid dependent patients with buprenorphine in an office-based setting. J Gen Intern Med 2007;22(2):171-6.
22. Fiellin DA, Pantalon MV, Pakes JP, O'Connor PG, Chawarski M, Schottenfeld RS. Treatment of heroin dependence with buprenorphine in primary care. Am J Drug Alcohol Abuse 2002;28(2):231-41.
23. O'Connor PG, Oliveto AH, Shi JM, et al. A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic. Am J Med 1998; 105(2):100-5.
24. Sullivan LE, Barry D, Moore BA, et al. A trial of integrated buprenorphine/ naloxone and HIV clinical care. Clin Infect Dis 2006;43(suppl 4):S184-S190.
25. Basu S, Smith-Rohrberg D, Bruce RD, Altice FL. Models for integrating buprenorphine therapy into the primary HIV care setting. Clin Infect Dis 2006;42(5):716-21.
26. Sullivan LE, Bruce RD, Haltiwanger D, et al. Initial strategies for integrating buprenorphine into HIV care settings in the United States. Clin Infect Dis 2006;43(suppl 4):S191-S196.